Navigation Links
Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
Date:8/6/2009

itute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offerings of the securities may be made only by means of a prospectus supplement and accompanying prospectus.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding expectations as to completion and timing of any public offering. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks and uncertainties related to the financial markets. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the SEC under the heading "Risk Factors" for a more detailed description of such factors, as well as Onyx's subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.538 04/2002 , ... , , , , ... , Cell type , Bacteria, gram ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , , ... , , , , , , , , ... Azotobacter vinelandii, , , ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 , ... , , , ... , Cell type , Bacteria, gram negative, ...
Cached Biology Technology:Bifidobacterium animalis 2Azotobacter vinelandii 2Actinomyces viscosus 2
(Date:4/21/2014)... mountains across the western United States are dying, thanks to ... inner bark. , Some species of the beetles, such ... Others live in dead, weakened or dying hosts. , In ... of more than 3.4 million acres of pine trees. , ... flow and water quality? Plenty, according to new research findings ...
(Date:4/21/2014)... are on the decline in the Galpagos. , A new ... indicates numbers of the iconic birds, known for their ... attract mates, have fallen more than 50 percent in less ... is probably due to an unexplained disappearance of sardines from ... at Wake Forest University and the study,s principal investigator. This ...
(Date:4/21/2014)... from Pittsburgh University, find how lipid mediators are ... Chemistry. Lipid mediators are molecules playing an important ... some of them has earned a Nobel prize ... power plants", the organelles where oxidation of various ... a molecule universally used for storage and transportation ...
Breaking Biology News(10 mins):Earth Week: Bark beetles change Rocky Mountain stream flows, affect water quality 2Earth Week: Bark beetles change Rocky Mountain stream flows, affect water quality 3Lack of breeding threatens blue-footed boobies' survival 2Lack of breeding threatens blue-footed boobies' survival 3The anti-inflammatory factory 2The anti-inflammatory factory 3
... of the Neanderthal genome persists in modern human populations. ... 665 people from Europe and East Asia shows that more ... DNA of this contemporary group, whose genetic information is part ... that someone of non-African descent may have inherited approximately 1 ...
... thousand years ago, Homo sapiens migrating out ... diverged from modern humans hundreds of thousands of years ... Neanderthals mingled, and over time, produced children with genes ... collision between two distinct populations remain alive in the ...
... a single gene in honey bees separates the queens from ... University and Wayne State University unraveled the gene,s inner workings ... Biology Letters . The gene, which is responsible for leg ... of bees, ability to carry pollen. "This gene is ...
Cached Biology News:Neanderthal lineages excavated from modern human genomes 2Neanderthal lineages excavated from modern human genomes 3When populations collide 2When populations collide 3When populations collide 4Single gene separates queen from workers 2